Related Experiment Video

Updated: Apr 3, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

14.4K

Emerging therapeutic approaches in renal cell carcinoma

Hiral Parekh1, Brian I Rini2,3

  • 1a 1 Cleveland Clinic, 9500 Euclid Ave, Cleveland, OH 44195, USA.

Expert Review of Anticancer Therapy
|September 18, 2015
PubMed

Insights

Targeted therapy has improved renal cell carcinoma outcomes, but metastatic disease remains challenging. Emerging immunotherapies, including checkpoint inhibitors, offer new hope for patients with advanced cancer.

Area of Science:

  • Oncology
  • Nephrology
  • Immunology

Background:

  • Targeted therapies (VEGF and mTOR inhibitors) have advanced renal cell carcinoma (RCC) treatment over the last decade.
  • Despite progress, metastatic RCC management remains difficult due to eventual progression on targeted therapies and limited long-term survival.
  • Cancer immunotherapy, particularly checkpoint inhibitors, is regaining prominence in oncology.

Purpose of the Study:

  • To review and optimize current targeted therapy standards for metastatic renal cell carcinoma.
  • To discuss emerging targeted therapies and immunotherapies for metastatic renal cell carcinoma.
  • To highlight the role of anti-programmed death-1 pathway inhibitors in managing advanced RCC.

Main Methods:

  • Literature review of targeted therapies for renal cell carcinoma.
  • Analysis of emerging targeted agents and immunotherapies.
  • Discussion of treatment strategies incorporating checkpoint inhibitors.

Main Results:

  • Current targeted therapies show significant benefits but are not curative for all metastatic RCC patients.
  • Emerging targeted therapies offer potential alternatives for treatment resistance.
  • Immunotherapies, especially anti-programmed death-1 agents, demonstrate promise in overcoming limitations of targeted therapy.

Conclusions:

  • Optimizing targeted therapy remains crucial for metastatic renal cell carcinoma.
  • Emerging targeted agents and immunotherapies represent the next frontier in advanced RCC treatment.
  • Integrating anti-programmed death-1 pathway inhibitors may improve outcomes for patients with metastatic renal cell carcinoma.
Keywords:
anti programmed death-1 therapiesimmunotherapyipilimumabnivolumabrenal cell carcinomatargeted therapy

More Related Videos

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers12:22

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

34.3K
Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Published on: April 29, 2014

17.3K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.3K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K